Immunotherapy for bladder cancer

预约门诊
打印

科室与专家门诊

妙佑医疗国际是美国规模最大、经验最丰富的医疗机构之一，在亚利桑那州、佛罗里达州和明尼苏达州都设有院区。我们的工作人员涉及数十种专业，通过齐心协力确保高品质治疗与成功康复。

有相关专长的科室

研究此手术的领域

行此手术的医生

编辑搜索过滤条件
close

缩小搜索范围

  1. 未找到姓氏以该字母开头的医生 A
  2. 未找到姓氏以该字母开头的医生 B
  3. 未找到姓氏以该字母开头的医生 C
  4. 未找到姓氏以该字母开头的医生 D
  5. 未找到姓氏以该字母开头的医生 E
  6. 未找到姓氏以该字母开头的医生 F
  7. 未找到姓氏以该字母开头的医生 G
  8. 未找到姓氏以该字母开头的医生 H
  9. 未找到姓氏以该字母开头的医生 I
  10. 未找到姓氏以该字母开头的医生 J
  11. 未找到姓氏以该字母开头的医生 K
  12. 未找到姓氏以该字母开头的医生 L
  13. 未找到姓氏以该字母开头的医生 M
  14. 未找到姓氏以该字母开头的医生 N
  15. 未找到姓氏以该字母开头的医生 O
  16. 未找到姓氏以该字母开头的医生 P
  17. 未找到姓氏以该字母开头的医生 Q
  18. 未找到姓氏以该字母开头的医生 R
  19. 查找姓氏以该字母开头的医生 S
  20. 查找姓氏以该字母开头的医生 T
  21. 未找到姓氏以该字母开头的医生 U
  22. 未找到姓氏以该字母开头的医生 V
  23. 未找到姓氏以该字母开头的医生 W
  24. 未找到姓氏以该字母开头的医生 X
  25. 未找到姓氏以该字母开头的医生 Y
  26. 未找到姓氏以该字母开头的医生 Z
重置所有过滤器

显示$起始范围 - $结束范围/源自可用$可用医生

  1. Paras H. Shah, M.D.

    Paras H. Shah, M.D.

    1. Urologist
    2. Oncologist
    1. Rochester, MN
    擅长领域：

    Nephrectomy, Partial nephrectomy, Laparoscopic kidney surgery, Laparoscopic surgery, Robotic prostatectomy, Robotic sur...gery, Urinary diversion, Prostatectomy, Bladder removal, Immunotherapy for bladder cancer, Benign prostatic hyperplasia, Prostate cancer, Bladder cancer, Kidney cancer, Ureteral cancer, Urothelial carcinoma, Metastatic bladder cancer, Recurrent bladder cancer, Non-muscle invasive bladder cancer

  2. Mark D. Tyson, II, M.D., M.P.H.

    Mark D. Tyson, II, M.D., M.P.H.

    1. Urologist
    1. Phoenix, AZ
    擅长领域：

    Neobladder reconstruction, Orchiectomy, Urinary conduit surgery, Bladder removal, Retroperitoneal lymph node dissection... for testicular cancer, Immunotherapy for bladder cancer, Bladder cancer surgery, Bladder cancer, Testicular cancer, Ureteral cancer, Urethral cancer, Urothelial carcinoma, Metastatic bladder cancer, Recurrent bladder cancer, Non-muscle invasive bladder cancer

Research Profiles

编辑搜索过滤条件
close

缩小搜索范围

查看所有医生 • 所有位置

来自妙佑医疗国际员工
申请预约
关于
Sept. 23, 2026
打印
  1. Keytruda (pembrolizumab) (prescribing information). Merck Sharp & Dohme LLC; 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287. Accessed Aug. 11, 2026.
  2. TICE BCG (prescribing information). Merck Sharp & Dohme LLC; 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9b74876-e665-442b-87ad-b7333bc9a67a. Accessed Aug. 11, 2026.
  3. Flaig TW, et al. Bladder cancer, Version 1, 2026. NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2026; doi:10.6004/jnccn.2026.0022.
  4. SEER Program Coding and Staging Manual 2026: Appendix C, coding guidelines for bladder. 2026. National Cancer Institute Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/manuals/2026/appendixc.html. Accessed Aug. 11, 2026.
  5. Chemotherapy and you: Support for people with cancer. National Cancer Institute. https://www.cancer.gov/publications/patient-education/chemo-and-you. Accessed Aug. 11, 2026.
  6. Padcev (prescribing information). Astellas Pharma US, Inc.; 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5631d3e-4604-4363-8f20-11dfc5a4a8ed. Accessed Aug. 11, 2026.
  7. De Santis M, et al. Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. The Lancet. 2025; doi:10.1016/S0140-6736(25)01897-5.
  8. Bavencio (prescribing information). EMD Serono, Inc.; 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cd725a1-2fa4-408a-a651-57a7b84b2118. Accessed Aug. 11, 2026.
  9. Van der Heijden MS, et al. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. New England Journal of Medicine. 2023; doi:10.1056/NEJMoa2309863.
  10. Imfinzi (prescribing information). AstraZeneca Pharmaceuticals LP; 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8baba4ea-2855-42fa-9bd9-5a7548d4cec3. Accessed Aug. 11, 2026.
  11. Opdivo (prescribing information). Bristol-Myers Squibb Company; 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394. Accessed Aug. 11, 2026.
  12. Anktiva (prescribing information). Altor BioScience, LLC; 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eae31db8-3e7a-d9e0-708d-74419d1b50ff. Accessed Aug. 11, 2026.
  13. Heiss BL, et al. FDA approval summary: Nogapendekin alfa inbakicept-pmln with BCG for BCG-unresponsive carcinoma in situ. Clinical Cancer Research. 2025; doi:10.1158/1078-0432.CCR-25-1231.
  14. Holzbeierlein JM, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. The Journal of Urology. 2024; doi:10.1097/JU.0000000000003846.
  15. Bladder cancer treatment (PDQ) — Health Professional Version. National Cancer Institute. Updated May 2, 2025. https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq. Accessed Aug. 11, 2026.
  16. Necchi A, et al. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): A single-arm, multicentre, phase 2 trial. The Lancet Oncology. 2024; doi:10.1016/S1470-2045(24)00178-5.
  17. Powles T, et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. New England Journal of Medicine. 2024; doi:10.1056/NEJMoa2408154.
  18. Galsky MD, et al. Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer. New England Journal of Medicine. 2026; doi:10.1056/NEJMoa2601486.
  19. Vulsteke C, et al. Perioperative enfortumab vedotin and pembrolizumab in bladder cancer. New England Journal of Medicine. 2026; doi:10.1056/NEJMoa2511674.
  20. Galsky MD, et al. Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274. Journal of Clinical Oncology. 2025; doi:10.1200/JCO.24.00340.
  21. Powles T, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. New England Journal of Medicine. 2024; doi:10.1056/NEJMoa2312117.
  22. Powles T, et al. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after 2 years of follow-up. Journal of Clinical Oncology. 2023; doi:10.1200/JCO.22.01792.
  23. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/SUO guideline (2017; amended 2020, 2024). American Urological Association. https://helpdesk.auanet.org/hc/en-us/articles/40948838469143-Guidelines. Accessed Aug. 11, 2026.
  24. Medical review (expert opinion). Mayo Clinic. Sept. 18, 2026.

相关

Immunotherapy for bladder cancer